Zofran and Zuplenz are medications prescribed to treat nausea and vomiting. They fall under a category of medications known as 5-HT3 receptor antagonists and have been proven to work. Problems arise, however, when the drugs are consumed by pregnant women. The drugs are linked to cases of congenital birth defects in babies. Lawsuits are being filed against the pharmaceutical manufacturer for damages. Medical Claim Legal can help those families obtain compensation.
Background of Zofran and Zuplenz
Zofran was first marketed and approved for distribution in 1991 by the medical manufacturer GlaxoSmithKline. By 2006 it had become the 20th highest selling drug in the country. Zofran works by limiting the amount of serotonin that gets to the part of the human brain that triggers nausea and vomiting. The FDA permitted the use of Zofran to surgery and cancer patients only. The drug still has not been approved by the FDA for use by pregnant women. Zuplenz is the spin-off drug of Zofran and has the exact same active ingredients, uses and side effects.
Why Zofran and Zuplenz are Dangerous
When pregnant women take Zofran or Zuplenz, the drugs have been linked to birth defects in newborn babies. Some of the most common birth defects are:
- Musculoskeletal abnormalities
- Club foot
- Cleft lip
- Cleft Palate
- Jaundice
- Heart deficiencies
Lawsuits Against GlaxoSmithKline
The claim against GSK is that it knew the drug could cause birth defects if used by pregnant women, but did not warn of these dangers. When lawsuits are brought against a pharmaceutical manufacturer such as GSK, they either end in a financial settlement for the plaintiff or the lawsuits go to trial. Generally, the lawsuits are settled prior to a trial.
Why Medical Claim Legal is Right For Your Case
Our team of experienced lawyers at Medical Claim Legal have years of experience in pharmaceutical litigation. Contacting us comes at no cost to you. We are ready to get you the best financial compensation possible.
MedicalClaimLegal, simplifying the process for Zofran and Zuplenz compensation.